全文获取类型
收费全文 | 12035篇 |
免费 | 560篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 263篇 |
儿科学 | 519篇 |
妇产科学 | 390篇 |
基础医学 | 1102篇 |
口腔科学 | 450篇 |
临床医学 | 997篇 |
内科学 | 2797篇 |
皮肤病学 | 225篇 |
神经病学 | 706篇 |
特种医学 | 652篇 |
外国民族医学 | 1篇 |
外科学 | 2317篇 |
综合类 | 292篇 |
一般理论 | 3篇 |
预防医学 | 506篇 |
眼科学 | 250篇 |
药学 | 662篇 |
中国医学 | 37篇 |
肿瘤学 | 512篇 |
出版年
2023年 | 108篇 |
2022年 | 230篇 |
2021年 | 392篇 |
2020年 | 206篇 |
2019年 | 281篇 |
2018年 | 331篇 |
2017年 | 249篇 |
2016年 | 379篇 |
2015年 | 448篇 |
2014年 | 541篇 |
2013年 | 637篇 |
2012年 | 794篇 |
2011年 | 802篇 |
2010年 | 497篇 |
2009年 | 454篇 |
2008年 | 791篇 |
2007年 | 885篇 |
2006年 | 864篇 |
2005年 | 792篇 |
2004年 | 693篇 |
2003年 | 553篇 |
2002年 | 484篇 |
2001年 | 92篇 |
2000年 | 85篇 |
1999年 | 84篇 |
1998年 | 114篇 |
1997年 | 103篇 |
1996年 | 107篇 |
1995年 | 71篇 |
1994年 | 61篇 |
1993年 | 59篇 |
1992年 | 30篇 |
1991年 | 31篇 |
1990年 | 40篇 |
1989年 | 45篇 |
1988年 | 42篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 27篇 |
1984年 | 12篇 |
1983年 | 19篇 |
1982年 | 24篇 |
1981年 | 8篇 |
1980年 | 15篇 |
1979年 | 11篇 |
1978年 | 12篇 |
1977年 | 10篇 |
1976年 | 11篇 |
1973年 | 10篇 |
1971年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 484 毫秒
131.
132.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
133.
134.
135.
136.
Asli Gamze Sener İlhan Afsar Mustafa Demirci 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2014,122(12):1167-1170
The presence of antinuclear antibodies (ANAs), directed against intracellular antigens, is a hallmark of systemic autoimmune rheumatic diseases. The indirect immunofluorescence (IIF) assay is among the most commonly used routine methods for ANA detection as the screening test. The objective of the study was to evaluate ANA patterns in a 4‐year period retrospectively. All 19 996 serum samples that were sent to the Laboratory of Medical Microbiology of the tertiary Hospital by any hospital department between 1 January 2009 and 1 January 2013 with a request to test for ANA, anti‐ENA or both were included in the study. Of these samples, 4375 (21.9%) were ANA‐IIF‐positive and 15621 (78.1%) were ANA‐IIF‐negative. The presented ANA‐positive samples consisted of 2392 (54.67%) homogenous, 818 (18.70%) speckled, 396 (9.05%) centromere, 242 (5.53%) nucleolar, 213 (4.87%) nuclear dots, 178 (4.07%) cytoplasmic (except for actin and golgi), 24 (0.55%) actin, 9 (0.21%) golgi, 53 (1.21%) nuclear membrane and 50 (1.14%) mixed pattern. Totally 7800 samples were examined by LIA. Of these samples, 3440 were positive and 4307 were negative with IIF and LIA. In addition, 22 samples were detected as IIF‐positive but LIA‐negative, whereas the rest 31 samples were IIF‐negative but LIA‐positive. ANA patterns in 22 IIF‐positive samples were homogenous (9), speckled (5), golgi (4), cytoplasmic (3) and nucleolar (1). SSA/Ro‐52, SSB/La and Scl‐70 positivity were detected in 31 IIF‐negative/LIA‐positive samples by LIA. The present study comes forward with its overall scope, which covers 4‐year data obtained in tertiary hospital located in the western part of Turkey. 相似文献
137.
138.
139.
140.
Sabri Tekin Hatice Özdoğan Mustafa Kemal Demir Hagar Soultan Sadia Zafar 《Transplantation proceedings》2021,53(4):1207-1210
Immunocompromised populations are at great risk of the current 2020 global emergency of coronavirus disease 2019 (COVID-19), and treatment of kidney transplant recipients with COVID-19 is currently not declared. Hence, the purpose of the study is to set a clear treatment regimen. We report here a therapeutic course of 2 patients who underwent transplant surgery in March 2020 and got infected soon after. Since the transplant, these 2 patients have received triple maintenance immunosuppressive therapy with oral tacrolimus, mycophenolate mofetil (MMF), and prednisone, and they have been regularly followed up at our hospital. The tacrolimus trough level was between 10 and 12 ng/mL. After the diagnosis of COVID-19, MMF was stopped and the tacrolimus dose was reduced so that blood level was between 4 and 6 ng/mL. The first patient was a 30-year-old man who, despite being treated with hydroxychloroquine, favipiravir, oseltamivir, and azithromycin therapy, died because of the presence of other comorbidities. The second case was a 58-year-old man who fully recovered from COVID-19 pneumonia with treatment with methylprednisolone, MMF, azithromycin, favipiravir, hydroxychloroquine, and reduction in immunosuppression dosage. This reflects the importance of using glucocorticoids in the treatment of COVID-19 along with other medications and the decreased mortality rate associated with their use. 相似文献